Ethylmalonate

Ethylmalonate

SCHEMBL83436

CCC(C(=O)[O-])C(=O)[O-].[K+].[K+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Ethylmalonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
TSHR P16473 2/20 0.43
NFKB1 P19838 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CA2 P00918 1/20 0.41
CA1 P00915 2/20 0.37
CA4 P22748 2/20 0.37
FFAR3 O14843 2/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC8 Q9BY41 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylmalonate SCHEMBL106344 0.97 CYP3A4 (0.42) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269202 0.97 CYP3A4 (0.46) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269251 0.97 CYP3A4 (0.42) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL8330729 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL9118939 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269702 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269525 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL5236393 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL9765249 0.94 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL108038 0.94 CYP3A4 (0.48) CYP3A4TSHRNFKB1NPSR1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118320360-A Easily-decomposed high-performance fire extinguishing coolant for aerosol fire extinguishing agent 湖北及安盾消防科技有限公司 2024-07-12 CN claimed
CN-115938640-A Acetic acid resistant solar cell silver paste and preparation method thereof 江西佳银科技有限公司 2023-04-07 CN claimed
CN-112358396-A Preparation process of ethyl isobutyrylacetate 门希国 2021-02-12 CN claimed
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US claimed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP claimed
EP-2190804-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2015-11-18 EP claimed
EP-1878493-B1 Method of making a polyisocyanurate/polyurethane foam using carbocation compounds as trimerization catalysts AIR PROD & CHEM (US) 2013-08-21 EP claimed
US-8324244-B2 Process and intermediates for preparing integrase inhibitors GILEAD SCIENCES, INC. (US) 2012-12-04 US claimed
US-8153801-B2 Process and intermediates for preparing integrase inhibitors GILEAD SCIENCES, INC. (US) 2012-04-10 US claimed
US-20110160458-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2011-06-30 US claimed
WO-2009036161-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-03-19 WO claimed
US-20080161560-A1 Process for Preparation of Calcium Salt of Rosuvastatin DESHPANDE PANDURANG BALWANT 2008-07-03 US claimed
WO-2008033836-A2 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-03-20 WO claimed
EP-1869005-A1 PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN UNICHEM LABORATORIES LIMITED (IN) 2007-12-26 EP claimed
WO-2006106526-A1 PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN UNICHEM LABORATORIES LIMITED (IN) 2006-10-12 WO claimed
CN-1092191-C Manufacture of cyclocarbonates HOFFMANN LA ROCHE (CH) 2002-10-09 CN claimed
EP-0950653-B1 Process for the preparation of potassium monoethylmalonate DEGUSSA (DE) 2001-11-21 EP claimed
EP-0950653-A1 Process for the preparation of potassium monoethylmalonate CREANOVA Spezialchemie GmbH (DE) 1999-10-20 EP claimed
CN-1180703-A Manufacture of cyclocarbonates HOFFMANN LA ROCHE (CH) 1998-05-06 CN claimed
EP-0652213-B1 Method for producing alkyl 3-phthalidylideneacetate SUMIKA FINE CHEMICALS CO LTD (JP) 1997-08-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS NUMA1, MNS1, ME1 CYP3A4 3906/4885TSHR 4737/4885NFKB1 275/4885
US-20080161560-A1 Process for Preparation of Calcium Salt of Rosuvastatin CACNA1C, CACNA1E, CACNA1S CYP3A4 583/4885TSHR 4414/4885NFKB1 1081/4885
US-20110160458-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB CYP3A4 14/4885TSHR 4554/4885NFKB1 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.